BioCentury
ARTICLE | Company News

Nicox’s Zerviate wins FDA nod for ocular itching

May 31, 2017 11:05 PM UTC

Nicox S.A. (Euronext:COX) jumped €2.26 (21%) to €12.85 Wednesday after FDA approved an NDA for Zerviate cetirizine to treat ocular itching associated with allergic conjunctivitis. The approval is Nicox's first in the U.S.

In October 2016, FDA issued a complete response letter for Zerviate, citing a GMP inspection at a third party facility (see BioCentury Extra, Oct. 10, 2016)...

BCIQ Company Profiles

Nicox S.A.